日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The Trial Bank initiative to promote trustworthy living evidence for medication safety (PROMISE) of children: design and pilot validation

旨在促进儿童用药安全可靠活体证据的试验库计划 (PROMISE):设计和试点验证

Xu, Chang; Doi, Suhail A; Vohra, Sunita; Furuya-Kanamori, Luis; Wang, Yingxia; Tang, Lijun; Tian, Yuan; Fan, Shiqi; Peng, Zhen; Mayo-Wilson, Evan; Lin, Lifeng; Chu, Haitao; Murad, M Hassan; Yu, Tianqi; Li, Sheyu; Chen, Yaolong; Golder, Su; Loke, Yoon; Clark, Justin; Glasziou, Paul; Du, Liang; Lin, Houwen; Gu, Zhichun

The hazards of using hazard ratios from proportional hazard models in indirect treatment comparisons

在间接治疗比较中使用比例风险模型中的风险比的风险

Jiang, Ziren; Liu, Jialing; He, Weili; Cappelleri, Joseph; Roychoudhury, Satrajit; Chen, Yong; Chu, Haitao

An alternative method for assessing the fragility of survival analysis results: a proof-of-concept study based on the log-rank test

评估生存分析结果脆弱性的另一种方法:基于对数秩检验的概念验证研究

Xing, Xing; Xing, Aiwen; Natarajan, Kannan; Chu, Haitao; Lin, Lifeng; Tong, Jiayi

Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison

劳拉替尼与阿来替尼治疗间变性淋巴瘤激酶阳性晚期/转移性非小细胞肺癌的长期疗效和安全性:匹配调整间接比较

Bauer, Todd; Abrahami, Devin; Polli, Anna; Chu, Haitao; Ramachandran, Priya; Chandler, Conor; Tan, Min; Truscott, James; Mazieres, Julien; Garcia, Christine A

Investigating the impact of problematic evidence on clinical practice guidelines and associated patient outcomes (VITALITY Study II): protocol

调查问题证据对临床实践指南及相关患者结局的影响(VITALITY 研究 II):方案

Xu, Chang; Furuya Kanamori, Luis; Cao, Hong; Wang, Xinyi; Loke, Yoon K; Li, Sheyu; Wen, Tianmeng; Fan, Shiqi; Gu, Zhichun; Stone, Jennifer C; Lin, Lifeng; Yisha, Zuhaer; Cristea, Ioana Alina; Du, Liang; Clark, Justin; Qin, Zongshi; Song, Yang; Zeng, Linan; Fan, Zhaohu; Golder, Su; Chu, Haitao; Murad, M Hassan; Lin, Houwen; Mol, Ben W; Vohra, Sunita; Doi, Suhail A

Investigating the impact of trial retractions on the healthcare evidence ecosystem (VITALITY Study I): retrospective cohort study

调查试验撤稿对医疗保健证据生态系统的影响(VITALITY 研究 I):回顾性队列研究

Xu, Chang; Fan, Shiqi; Tian, Yuan; Liu, Fuchen; Furuya-Kanamori, Luis; Clark, Justin; Zhang, Chao; Li, Sheng; Lin, Lifeng; Chu, Haitao; Li, Sheyu; Golder, Su; Loke, Yoon; Vohra, Sunita; Glasziou, Paul; Doi, Suhail A; Liu, Hui

Tipping point analysis in network meta-analysis

网络荟萃分析中的临界点分析

Wang, Zheng; Murray, Thomas A; Han, Wenshan; Lin, Lifeng; Siegel, Lianne K; Chu, Haitao

ZIBGLMM: Zero-inflated bivariate generalized linear mixed model for meta-analysis with double-zero-event studies

ZIBGLMM:用于双零事件研究荟萃分析的零膨胀双变量广义线性混合模型

Li, Lu; Lin, Lifeng; Cappelleri, Joseph C; Chu, Haitao; Chen, Yong

A critical assessment of matching-adjusted indirect comparisons in relation to target populations

对与目标人群相关的匹配调整间接比较进行批判性评估

Jiang, Ziren; Liu, Jialing; Alemayehu, Demissie; Cappelleri, Joseph C; Abrahami, Devin; Chen, Yong; Chu, Haitao

Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results

经匹配调整的间接比较Elranatamab与Teclistamab在三线抗癌治疗/难治性多发性骨髓瘤患者中的疗效:最新结果

Mol, Isha; Hu, Yannan; LeBlanc, Thomas W; Cappelleri, Joseph C; Chu, Haitao; Nador, Guido; Aydin, Didem; Perez Cruz, Isabel; Hlavacek, Patrick